Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001193125-25-207734·CG Oncology, Inc.
Schedule 13D ownership disclosure
CG oncology Inc
Common Stock, $0.0001 par value per share · CUSIP: 156944100
Event date: 2025-09-11
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Longitude Capital Partners IV, LLCReported CIK 0001829169
Shares: 3,190,463 · Class: 4.1%
- Longitude Venture Partners IV, L.P.Reported CIK 0001787456
Shares: 3,190,463 · Class: 4.1%
- Longitude Prime Partners, LLCReported CIK 0001865779
Shares: 1,471,805 · Class: 1.9%
- Longitude Prime Fund, L.P.Reported CIK 0001865844
Shares: 1,471,805 · Class: 1.9%
- Patrick G. EnrightReported CIK 0001253886
Shares: 4,662,268 · Class: 6.0%
- Juliet Tammenoms BakkerReported CIK 0001431159
Shares: 4,662,268 · Class: 6.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-207734
- Form type
- SCHEDULE 13D
- Filer
- CG Oncology, Inc.
- CIK
- CIK 1991792
- Filed
- Sep 18, 2025
- Reporting period
- Sep 11, 2025
- Description
- Schedule 13D beneficial ownership